Related Experiment Videos
[Initial results in tumor diagnosis with radioactive lanthanide complexes]
W G Franke1, T Schmiedel, A Grundmann
1Klinik und Poliklinik für Nuklearmedizin, Medizinische Akademie Dresden, FRG.
Nuklearmedizin. Nuclear Medicine
|August 1, 1993
Summary
This study shows that 169Yb-labelled metal ligand complexes effectively image tumors in patients. Good to excellent tumor imaging was achieved in most cases, enabling diagnosis within hours of injection.
Area of Science:
- Nuclear medicine
- Radiopharmaceutical research
- Oncology
Background:
- Previous animal studies suggested tumor accumulation of 169Yb-labelled metal ligand complexes.
- The diagnostic potential in humans remained to be confirmed.
Purpose of the Study:
- To evaluate the tumor-imaging capabilities of 169Yb-labelled metal ligand complexes in a clinical setting.
- To assess the time course and diagnostic utility of these radiopharmaceuticals.
Main Methods:
- Clinical investigation involving 70 patients.
- Intravenous injection of 169Yb-labelled metal ligand complexes.
- Assessment of radiopharmaceutical distribution in tumors, skeleton, and liver.
Main Results:
- Good to excellent tumor imaging was achieved in 61 out of 70 patients (87%).
- Meaningful diagnoses were possible within 2-5 hours post-injection.
- Identified lesions not detectable by other imaging modalities, interpreted as metastases.
Conclusions:
- 169Yb-labelled metal ligand complexes demonstrate significant potential for clinical tumor imaging.
- The radiopharmaceuticals offer a rapid and effective diagnostic tool for detecting various tumors and metastases.